Table 3.
Univariate and multivariable Cox regression analyses for the development of LC complication after 1-year CT
| Variable | Univariate |
Model 1 |
Model 2 |
Model 3 |
||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P-value | aHR (95% CI) | P-value | aHR (95% CI) | P-value | aHR (95% CI) | P-value | |
| Age (years) | 1.02 (0.99–1.05) | 0.19 | ||||||
| Gender, male | 1.06 (0.68–1.66) | 0.80 | ||||||
| BMI (kg/m2) | 0.95 (0.89–1.02) | 0.13 | ||||||
| HTN | 1.79 (1.15–2.79) | 0.01 | 2.07 (1.21–3.54) | <0.01 | 1.93 (1.16–3.21) | 0.01 | 2.03 (1.20–3.42) | <0.01 |
| DM | 1.82 (1.18–2.80) | <0.01 | 1.17 (0.72–1.93) | 0.53 | 1.12 (0.69–1.82) | 0.65 | 1.23 (0.76–2.00) | 0.40 |
| Alcohol-related | 4.48 (2.93–6.86) | <0.01 | 2.00 (1.22–3.28) | <0.01 | 2.22 (1.38–3.59) | <0.01 | 1.99 (1.22–3.24) | <0.01 |
| Hepatitis B | 0.20 (0.13–0.33) | <0.01 | 0.37 (0.21–0.66) | <0.01 | 0.33 (0.19–0.58) | <0.01 | 0.38 (0.22–0.68) | <0.01 |
| Hepatitis C | 0.48 (0.15–1.52) | 0.21 | ||||||
| Platelets (×109/L) | 0.99 (0.98–0.99) | <0.01 | 1.00 (0.99–1.00) | 0.10 | 0.99 (0.98–1.00) | <0.01 | 1.00 (0.99–1.00) | 0.14 |
| Albumin (g/dL) | 0.14 (0.10–0.19) | <0.01 | 0.33 (0.18–0.61) | <0.01 | 0.32 (0.17–0.60) | <0.01 | ||
| AST (U/L) | 1.01 (1.00–1.01) | <0.01 | 1.01 (1.00–1.01) | <0.01 | 1.01 (1.00–1.02) | <0.01 | 1.01 (1.00–1.01) | <0.01 |
| ALT (U/L) | 1.01 (1.00–1.01) | 0.01 | 0.99 (0.98–1.00) | 0.14 | 0.99 (0.98–1.00) | 0.12 | 0.99 (0.98–1.01) | 0.15 |
| Bilirubin (mg/dL) | 1.67 (1.48–1.89) | <0.01 | 0.97 (0.74–1.27) | 0.83 | ||||
| Prothrombin time (INR) | 17.85 (9.34–34.11) | <0.01 | 0.83 (0.22–3.11) | 0.78 | ||||
| Creatinine (mg/dL) | 0.50 (0.14–1.76) | 0.28 | ||||||
| eGFR (mL/min/1.73 m2) | 1.01 (1.00–1.03) | <0.01 | 1.00 (0.99–1.01) | 0.96 | 1.00 (0.99–1.01) | 0.70 | 1.00 (0.99–1.01) | 0.81 |
| Sodium (mmol/L) | 0.81 (0.76–0.86) | <0.01 | 0.96 (0.89–1.04) | 0.35 | 0.92 (0.86–0.99) | 0.03 | ||
| Ascites | 12.17 (7.64–19.38) | <0.01 | 1.96 (0.98–3.91) | 0.06 | 2.08 (1.04–4.14) | 0.04 | ||
| Child-Pugh score | 1.77 (1.61–1.95) | <0.01 | 1.35 (1.19–1.54) | <0.01 | ||||
| Child-Pugh class, B/C | 10.87 (6.94–17.02) | <0.01 | ||||||
| MELD-Na score | 1.25 (1.20–1.31) | <0.01 | 0.99 (0.92–1.08) | 0.87 | ||||
| Sarcopenia | 1.31 (0.78–2.21) | 0.30 | ||||||
| SMI (cm2/m2) | 0.98 (0.96–1.01) | 0.12 | ||||||
| ∆SMI/yr% (%) | 0.95 (0.93–0.97) | <0.01 | 0.96 (0.93–0.98) | <0.01 | 0.96 (0.93–0.98) | <0.01 | 0.95 (0.93–0.98) | <0.01 |
The values of variables were derived by examinations at the 1-year follow-up.
Model 1, multivariable Cox regression analysis with HTN, DM, alcohol, hepatitis B, platelet count, albumin, AST, ALT, bilirubin, INR, sodium, presence of ascites, and ΔSMI/yr%, which showed P<0.01 in univariate analyses, except for the conventional prognostic models including Child-Pugh and MELD-Na scores; model 2, multivariable Cox regression analysis with model 1 and Child-Pugh score but excluding the components of Child-Pugh score; model 3, multivariable Cox regression analysis with model 1 and MELD-Na score, but excluding the components of the MELD-Na score.
LC, liver cirrhosis; CT, computed tomography; HR, hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio; BMI, body mass index; HTN, hypertension; DM, diabetes mellitus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalized ratio; eGFR, estimated glomerular filtration rate; MELD, model for end-stage liver disease; SMI, skeletal muscle index; ΔSMI/yr%, % change in SMI after 1 year.